在乙酸诱导的性结肠炎模型中,皮米宁的抗炎活性
Maryam Ranjbar Bushehri1, Nahid Babaei1, Hadi Esmaeili Gouvarchin Ghaleh2
1Department of Molecular Cell Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran.
来自Fritillaria imperialis的化合物Peiminine在实验性性结肠炎模型中有效降低了炎症和组织损伤. 这种天然化合物通过向关键炎症途径,显示出对治疗性结肠炎的前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 自然产品 化学 化学
背景情况:
- 性结肠炎是一种慢性炎症性肠病,影响肠道粘膜.
- 皮米宁来自Fritillaria imperialis,具有已知的抗炎和抗癌特性.
研究的目的:
- 在酸诱导的性结肠炎实验模型中研究皮米宁的抗炎作用.
- 评估皮米宁对关键炎症标志物和结肠组织损伤的影响.
主要方法:
- 性结肠炎在小鼠中被诱导使用直肠内乙酸.
- 佩米宁治疗是在诱导后进行的,在第15天进行评估.
- 评估的参数包括疾病活性指数,髓氧化酶活性,氧化,促炎性细胞因子 (IL-1,IL-6,TNF-α) 和基因表达 (IL-1β,IL-6,TNF-α,iNOS,COX2).
主要成果:
- 皮米宁治疗显著降低了氧化,髓氧化酶活性以及IL-1β,IL-6和TNF-α的水平.
- 观察到IL-1β,IL-6,TNF-α,iNOS和COX2的基因表达减少.
- 组织病理学分析表明减轻了肠道组织损伤.
结论:
- 皮米宁在实验性性结肠炎模型中显示出显著的抗炎作用.
- 该化合物减轻炎症表现,并保护肠道组织免受损伤.
- 皮米宁显示出作为治疗性结肠炎管理的治疗剂的潜力.
更多相关视频
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
